Frontlight ResearchEarly access
CompletedPhase 2
Antimalarial prophylactic efficacy of a weekly dose atovaquone-proguanil
Key facts
- Who runs it
- Universitaetsklinikum Tuebingen AöR
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 32 people enrolled
- Started
- 12 Nov 2025
- Ended
- 9 Sept 2026
- Type of study
- Interventional
- Record updated
- 11 June 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 40 criteriaShow less
Who can take part
- Healthy malaria-naive adults aged 18 to 40 years
- Willingness to take AP or placebo at the scheduled timepoint and a curative antimalarial regimen following CHMI and development of amplifying parasitaemia
- Answer all questions on the informed consent quiz correctly
- Able and willing (in the Investigator’s opinion) to comply with all study requirements
- Willing to allow the investigators to discuss the volunteer’s medical history with their general practitioner if required
- Residence in or nearby Tübingen with a maximum travel time to our study centre of 1 hour for the study period
- Women who agree to practice effective contraception for the duration of the study (a method which results in a low failure rate; i.e. less than 1% per year)
- Weight over 40 kg and BMI ≥19 and ≤ 30
- Agreement to refrain from blood donation during the course of the study and after the end of their involvement in the study according to the local and national blood banking eligibility criteria
- Provision of written informed consent to receive PfSPZ Challenge (NF54) for CHMI
- Reachable (24/7) by mobile phone during the CHMI period
Who cannot take part
- Use of chronic (more than 14 days) systemic immunosuppressive medication within the past 2 years (topical or inhaled immunosuppressive agents are allowed)
- Use of immunoglobulins or blood products within 3 months prior to enrolment
- History of travel to a malaria-endemic country within the previous 12 months
- Suspected or known illicit drug abuse in the 5 years preceding enrolment
- Intake of medication that potentially interferes with the study intervention or rescue drugs
- Prior receipt of malaria vaccine candidates or malaria challenge products
- Use of concomitant medication with anti-plasmodial activity within 30 days of study enrolment (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin erythromycin, fluoroquinolones, or azithromycin)
- Receipt of an investigational product in the 90 days preceding, or planned receipt during the study period
- Contraindication to the use of the following antimalarial medications: AP, artemether-lumefantrine, artesunate
- Use of medication interacting with AP (e.g. metoclopramide, tetracycline, rifampicin, rifabutin, efavirenz, or nevirapine)
- Use of medication interacting with artemether-lumefantrine (e.g. disopyramide, quinidine, procainamide, amiodarone, rifampicin, carbamazepine, phenytoin, phenobarbital, haloperidol, domperidone, pimozide or pipamperone)
- History of malaria
- History of seizure (except uncomplicated febrile convulsion at childhood)
- Diagnosis of any immune deficiency disorder, including human immunodeficiency virus (HIV) infection
- History of (functional) asplenia
- Any other confirmed or suspected immunosuppressive or immunodeficient state (e.g., repeated and/or unusual infection), including history of infection caused by opportunistic organisms, any infection or combination of infections that suggest underlying immunodeficiency, history of meningitis, encephalitis, septic shock, life-threatening soft tissue infection, more than one pneumonia
- History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
- Any other serious chronic illness requiring hospital specialist supervision
- History of serious psychiatric condition that may affect participation in the study
- Any other significant disease, disorder, finding at medical history, biochemistry, haematology tests, urine analysis results, clinical examination or electrocardiogram (ECG) which, in the opinion of the Investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
- Positive for hepatitis B surface antigen (HBs-antigen)
- Seropositive for hepatitis C virus (antibodies to HCV)
- Known (or signs consistent with) sickle cell anemia, sickle cell trait, thalassemia or thalassemia trait, glucose-6-phosphate dehydrogenase deficiency
- Pregnancy, lactation or intention to become pregnant during the study
- Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 24 g (men) or 12 g (women) per day
- Volunteers unable to be closely followed for social, geographic or psychological reasons
- Difficulties with venepuncture for blood sampling at screening visit due to veins that easily collapse or roll, are too thin, or are hard to find
- Abnormal vital signs
- Residence in a malaria endemic area for 5 or more years continuously
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The overall primary objective is to evaluate the prophylactic efficacy of a weekly dose administration of oral AP 250/100 mg in non-immune healthy volunteers exposed to malaria by intravenous administration of heterologous PfSPZ Challenge (NF54).
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 11 June 2026